



(12) Patent specification

(10) SE 539 575 C2

(21) Patent application number:	1551050-6	(51) Int.Cl.:	
(45) Grant of patent:	2017-10-17	A61K 31/721	(2006.01)
(41) Available to the public:	2017-01-31	A61P 9/10	(2006.01)
(22) Filing date:	2015-07-30	C08B 37/02	(2006.01)
(24) Effective date:	2015-07-30	C08L 5/02	(2006.01)
(30) Priority data:	---		

- (73) Patentee: TX MEDIC AB, Box 81, SE-263 03 Viken SE
- (72) Inventor: Lars BRUCE, Viken SE
Adam BRUCE, Viken SE
Anders WAAS, Göteborg SE
- (74) Agent: AROS PATENT AB, Box 1544, SE-751 45, UPPSALA SE
- (54) Title: Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
- (56) Cited documents: WO 9722347 A1 · CN 102973593 A · US 20040224922 A1 · BANZ, Y. et al, 'Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury' Eur Heart J, 2005, vol. 26, p. 2334-2343 · KRENNING, G. et al, 'The Origin of Fibroblasts and Mechanism of Cardiac Fibrosis' J Cell Physio, 2010, vol. 225, p. 631-637 · MERCER, P. F. et al 'Coagulation and coagulation signalling in fibrosis' Biochim Biophys Acta, 2013, p. 1018-1027 · Dextran sulfate product specification [online] Sigma Aldrich [retrieved on 19-09-2016] Retrieved from the Internet: <URL: http://www.sigmaaldrich.com/Graphics/COFAInfo/SigmaSAPQM/SPEC/D7/D7037/D7037-BULK_____SIAL_____.pdf> · Dextran sulfate product information [online] Sigma Aldrich [retrieved on 19-09-2016] Retrieved from the Internet: <URL: <https://www.sigmaaldrich.com/content/dam/sigma->
- (57) Abstract:

The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject having suffered from myocardial infarction or myocardial ischemia.